Journal of Thrombosis and Haemostasis

Forthcoming articles in the March issue
pp. xiv-xv(1)

International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)
pp. 295-306(12)
Authors: MIYAKIS, S.; LOCKSHIN, M. D.; ATSUMI, T.; BRANCH, D. W.; BREY, R. L.; CERVERA, R.; DERKSEN, R. H. W. M.; DE GROOT, P. G.; KOIKE, T.; MERONI, P. L.; REBER, G.; SHOENFELD, Y.; TINCANI, A.; VLACHOYIANNOPOULOS, P. G.; KRILIS, S. A.

Are B vitamins a risk factor for venous thromboembolism? Yes
pp. 307-308(2)
Author: EICHINGER, S.

Are B vitamins a risk factor for VTE? Perhaps
pp. 309-311(3)
Author: DEN HEIJER, M.

Platelet function analyzer (PFA)-100^® closure time in the evaluation of platelet disorders and platelet function
pp. 312-319(8)
Authors: HAYWARD, C. P. M.; HARRISON, P.; CATTANEO, M.; ORTEL, T. L.; RAO, A. K.

Protease nexin-1: a regulator of vascular disease?
pp. 320-321(2)
Authors: FERRONI, P.; GUADAGNI, F.

The serpin protease nexin-1 regulates vascular smooth muscle cell adhesion, spreading, migration and response to thrombin
pp. 322-328(7)
Authors: RICHARD, B.; PICHON, S.; AROCAS, V.; VENISSE, L.; BERROU, E.; BRYCKAERT, M.; JANDROT-PERRUS, M.; BOUTON, M.-C.

Attack of the acronyms: TTP, VWF, ADAMTS-13 and SELDI-TOF-MS
pp. 329-332(4)
Authors: AUTON, M.; MOAKE, J.

A rapid test for the diagnosis of thrombotic thrombocytopenic purpura using surface enhanced laser desorption/ionization time-of-flight (SELDI-TOF)-mass spectrometry
pp. 333-338(6)
Authors: JIN, M.; CATALAND, S.; BISSELL, M.; WU, H. M.

When is cardiovascular genomics delivering on its promise?
pp. 339-340(2)
Author: REITSMA, P. H.

Multi-locus candidate gene polymorphisms and risk of myocardial infarction: a population-based, prospective genetic analysis
pp. 341-348(8)
Authors: ZEE, R. Y. L.; COOK, N. R.; CHENG, S.; ERLICH, H. A.; LINDPAINTNER, K.; RIDKER, P. M.

Comparative RNA expression analyses from small-scale, single-donor platelet samples
pp. 349-356(8)
Authors: HILLMANN, A. G.; HARMON, S.; PARK, S. D. E.; O'BRIEN, J.; SHIELDS, D. C.; Kenny, D.

Factor VIII and von Willebrand factor changes after desmopressin and during pregnancy in type 2M von Willebrand disease Vicenza: a prospective study comparing patients with single (R1205H) and double (R1205H-M740I) defect
pp. 357-360(4)
Authors: CASTAMAN, G.; FEDERICI, A. B.; BERNARDI, M.; MORONI, B.; BERTONCELLO, K.; RODEGHIERO, F.

Activated protein C resistance – in the absence of factor V Leiden – and pregnancy
pp. 361-366(6)
Authors: LINDQVIST, P. G.; SVENSSON, P.; DAHLBÄCK, B.

A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors
pp. 367-371(5)
Authors: SANTAGOSTINO, E.; MANCUSO, M. E.; ROCINO, A.; MANCUSO, G.; SCARAGGI, F.; MANNUCCI, P. M.

Thrombin generation time is a novel parameter for monitoring enoxaparin therapy in patients with end-stage renal disease
pp. 372-376(5)
Authors: BROPHY, D. F.; MARTIN, E. J.; GEHR, T. W. B.; BEST, A. M.; PAUL, K.; CARR, M. E.

The measurement of low levels of factor VIII or factor IX in hemophilia A and hemophilia B plasma by clot waveform analysis and thrombin generation assay
pp. 377-384(8)
Authors: MATSUMOTO, T.; SHIMA, M.; TAKEYAMA, M.; YOSHIDA, K.; TANAKA, I.; SAKURAI, Y.; GILES, A. R.; YOSHIOKA, A.

Protein S multimers and monomers each have direct anticoagulant activity
pp. 385-391(7)
Authors: HEEB, M. J.; SCHUCK, P.; XU, X.

Limited generation of activated protein C during infusion of the protein C activator thrombin analog W215A/E217A in primates
pp. 392-397(6)
Authors: GRUBER, A.; FERNÁNDEZ, J. A.; BUSH, L.; MARZEC, U.; GRIFFIN, J. H.; HANSON, S. R.; DI CERA, E.

Association of increased fibrinogen concentration with impaired activation of anticoagulant protein C
pp. 398-402(5)
Authors: DÍEZ, N.; MONTES, R.; ALONSO, Á.; MEDINA, P.; NAVARRO, S.; ESPAÑA, F.; HERMIDA, J.

Murine model of ferric chloride-induced vena cava thrombosis: evidence for effect of potato carboxypeptidase inhibitor
pp. 403-410(8)
Authors: WANG, X.; SMITH, P. L.; HSU, M.-Y.; OGLETREE, M. L.; SCHUMACHER, W. A.

Validation of rotation thrombelastography in a model of systemic activation of fibrinolysis and coagulation in humans
pp. 411-416(6)
Authors: SPIEL, A. O.; MAYR, F. B.; FIRBAS, C.; QUEHENBERGER, P.; JILMA, B.

The interaction of von Willebrand factor-A1 domain with collagen: mutation G1324S (type 2M von Willebrand disease) impairs the conformational change in A1 domain induced by collagen
pp. 417-425(9)
Authors: MORALES, L. D.; MARTIN, C.; CRUZ, M. A.

Lentivirus degradation and DC-SIGN expression by human platelets and megakaryocytes
pp. 426-435(10)
Authors: BOUKOUR, S.; MASSÉ, J.-M.; BÉNIT, L.; DUBART-KUPPERSCHMITT, A.; CRAMER, E. M.

Megakaryocytes derived from human embryonic stem cells: a genetically tractable system to study megakaryocytopoiesis and integrin function
pp. 436-442(7)
Authors: GAUR, M.; KAMATA, T.; WANG, S.; MORAN, B.; SHATTIL, S. J.; LEAVITT, A. D.

ERK2 activation in arteriolar and venular murine thrombosis: platelet receptor GPIb vs. P2X₁
pp. 443-452(10)
Authors: OURY, C.; DAENENS, K.; HU, H.; TOTH-ZSAMBOKI, E.; BRYCKAERT, M.; HOYLAERTS, M. F.

Nicotine induces tissue factor expression in cultured endothelial and smooth muscle cells
pp. 453-458(6)
Authors: CIRILLO, P.; DE ROSA, S.; PACILEO, M.; GARGIULO, A.; LEONARDI, A.; ANGRI, V.; FORMISANO, S.; CHIARIELLO, M.

Function-blocking antithrombospondin-1 monoclonal antibodies
pp. 459-468(10)
Authors: ANNIS, D. S.; MURPHY-ULLRICH, J. E.; MOSHER, D. F.

Anti-HCV agent, ribavirin, elevates the activity of clotting factor VII in patients with hemophilia: a possible mechanism of decreased events of bleeding in patients with hemophilia by ribavirin
pp. 469-470(2)
Authors: YAMAMOTO, K.; HONDA, T.; MATSUSHITA, T.; KOJIMA, T.; TAKAMATSU, J.

An intronic mutation within FGB (IVS1+2076 a→g) is associated with afibrinogenemia and recurrent transient ischemic attacks
pp. 471-472(2)
Authors: DEAR, A.; DALY, J.; BRENNAN, S. O.; TUCKFIELD, A.; GEORGE, P. M.

Population variation in VKORC1 haplotype structure
pp. 473-474(2)
Authors: MARSH, S.; KING, C. R.; PORCHE-SORBET, R. M.; SCOTT-HORTON, T. J.; EBY, C. S.

Haplotypes of the fibrinogen gamma gene do not affect the risk of myocardial infarction
pp. 474-476(3)
Authors: UITTE DE WILLIGE, S.; DOGGEN, C. J. M.; DE VISSER, M. C. H.; BERTINA, R. M.; ROSENDAAL, F. R.

Statins modulate expression of components of the plasminogen activator/plasmin system in human cardiac myocytes in vitro
pp. 476-479(4)
Authors: DEMYANETS, S.; KAUN, C.; MAURER, G.; HUBER, K.; WOJTA, J.

A new method for assessment of an anti-5HT_2A agent, sarpogrelate hydrochloride, on platelet aggregation
pp. 479-481(3)
Authors: SATOH, K.; YATOMI, Y.; OZAKI, Y.

Factor V deficiency caused by a novel missense mutation, Ile417Thr, in the A2 domain
pp. 481-483(3)
Authors: KLING, S. J.; GRIFFEE, M.; FLANDERS, M. M.; RODGERS, G. M.

Screening for bleeding disorders in women with menorrhagia using a platelet function analyzer
pp. 483-485(3)
Authors: VEYRADIER, A.; GERVAISE, A.; BOYER-NEUMANN, C.; WOLF, M.; FERNANDEZ, H.

More on: aspirin resistance: position paper of the Working Group on Aspirin Resistance. Proposal for a Laboratory Test Guiding Algorithm
pp. 485-487(3)
Authors: PULCINELLI, F. M.; RIONDINO, S.

Announcements
pp. 488-488(1)